Novocure is a global oncology company with commercial-stage operations in the United States that develops and commercializes Tumor Treating Fields therapy to extend survival in some of the most aggressive forms of cancer. Its pipeline includes ovarian cancer, pancreatic cancer, non-small cell lung cancer, and brain metastasis, and it has ongoing or completed clinical trials investigating Tumor Treating Fields in various other forms of cancer. Headquartered in Switzerland, Novocure has operations in the United States, Germany, Jersey, Japan, and Israel.